Previous 10 | Next 10 |
AlloVir press release ( NASDAQ: ALVR ): Q2 GAAP EPS of $0.69 beats by $1.42 . For the quarter ended June 30, 2022, net loss was $44.6 million or $0.69 per share, compared with a net loss of $37.6 million or $0.60 per share for the quarter ended June 30, 2021. For...
Three Phase 3 Posoleucel Registrational Trials Continue to Expand Globally, Enrolling Patients in the U.S., Europe and Asia Company Is On Track to Release Final Results of Posoleucel Phase 2 Multi-Virus Prevention Study at Year-End and Topline Results of Phase 2 BKV Treatment ...
Community Health Systems CYH -45% on Q2 results. Coursera COUR -37% on Q2 results. Ranpak Holdings PACK -31% on Q2 results. Teladoc Health TDOC -22% . on Q2 results. Lexicon Pharmaceuticals LXRX -21% on pricing $85M stock offering ...
Gainers: Blue Water Vaccines ( BWV ) +69% . Leafly Holdings ( LFLY ) +25% . AlloVir ( ALVR ) +23% . Teva Pharmaceutical ( TEVA ) +21% . Nutriband ( NTRB ) +17% . Losers: ObsEva ( OBSV ) -68% . Cassava Scie...
AlloVir ( NASDAQ: ALVR ) shares gained over 8% pre-market on Wednesday after the immunotherapy company announced a $126.6M securities offering. The firm entered into a securities purchase agreement with a group of institutional and strategic investors to sell ~25.46M s...
Proceeds Support the Completion of Three Global Phase 3 Registrational Trials for Posoleucel and Global Regulatory Filings AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage allogeneic T-cell immunotherapy company, today announced that it has entered into a securities purch...
Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...
Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...
AlloVir (NASDAQ:ALVR) on Tuesday announced preliminary, blinded data from its ongoing phase 2 study of its T cell therapy posoleucel for the treatment of BK viremia in adults who have got kidney transplant. BK viremia is a common infection encountered after kidney transplantation. It can put ...
Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization) ...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...